P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

• Nicolas Boissel,
• Patrice Chevallier,
• Kevin Curran,
• Gary Schiller,
• Hongtau Liu,
• Richard Larson,
• Daniel J. Deangelo,
• Jean-Baptiste Mear,
• Stephan Grupp,
• André Baruchel,
• Marina Konopleva,
• Alexandra Lacroce,
• Caroline Roudet,
• Ana Korngold,
• Katie Newhall,
• Eric Laille,
• Daniel Lee,
• Mark Frattini,
• Nitin Jain

Affiliations

Nicolas Boissel

1 Hôpital St Louis, Assistance Publique – Hôpitaux de Paris, Paris, France

Patrice Chevallier

2 Hôtel-Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France

Kevin Curran

3 Memorial Sloan-Kettering Cancer Center, New York, United States

Gary Schiller

4 David Geffen School of Medicine at UCLA, Los Angeles, United States

Hongtau Liu

5 University of Chicago, Chicago, United States

Richard Larson

5 University of Chicago, Chicago, United States

Daniel J. Deangelo

6 Dana-Farber Cancer Institute, Boston, United States

Jean-Baptiste Mear

7 Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France

Stephan Grupp

8 Children’s Hospital of Philadelphia, Philadelphia, United States

André Baruchel

9 Hôpital Robert Debré, Assistance Publique – Hôpitaux de Paris, Paris, France

Marina Konopleva

10 Albert Einstein College of Medicine, New York, United States

Alexandra Lacroce

11 Cellectis, Inc., New York, United States

Caroline Roudet

11 Cellectis, Inc., New York, United States

Ana Korngold

11 Cellectis, Inc., New York, United States

Katie Newhall

11 Cellectis, Inc., New York, United States

Eric Laille

11 Cellectis, Inc., New York, United States

Daniel Lee

11 Cellectis, Inc., New York, United States

Mark Frattini

11 Cellectis, Inc., New York, United States

Nitin Jain

12 MD Anderson Cancer Center, Houston, United States